Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia 1

Interventions

Cyclophosphamide 14fludarabine phosphate 13ruxolitinib 9Busulfan 9Antilymphocyte Serum 9fludarabine 8Peripheral Blood Stem Cell Transplantation 8Filgrastim 8Whole-Body Irradiation 7Cyclosporine 7Tacrolimus 6Radiotherapy 6Mycophenolic Acid 6Methylprednisolone 6Methotrexate 5Melphalan 5Cytarabine 5Cord Blood Stem Cell Transplantation 5Azacitidine 5Imatinib Mesylate 4Alemtuzumab 4ponatinib 3parsaclisib 3fedratinib 3Stem Cell Transplantation 3Rituximab 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Decitabine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Myeloproliferative Disorders × zileuton × Clear all
NCT01130688 2015-05-27

Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.

University of Massachusetts, Worcester

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡